source
- Moderna shares surge as Merck-Moderna mRNA melanoma vaccine meets Phase 3 endpointMerck and Moderna reported that their personalized mRNA cancer vaccine, combined with Merck’s Keytruda, slowed melanoma recurrence in a Phase 3 study. The interim analysis showed a statistically si…
- Moderna-Merck mRNA cancer vaccine shows landmark interim success in melanoma trialAn interim analysis of a Phase 3 trial of an individualized mRNA cancer vaccine from Moderna and Merck showed the treatment met its primary goals. The vaccine, given together with Merck's immunothe…